Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis - Wikidata - awgldk - TriplyDB

Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis

Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis

http://www.wikidata.org/entity/Q24290682

about

Cardiomyopathy classification: ongoing debate in the genomics era Coarctation of the aorta and mild to moderate developmental delay in a child with a de novo deletion of chromosome 15(q21.1q22.2)Deciphering the design of the tropomyosin molecule Thin filament mutations: developing an integrative approach to a complex disorder On predictors of sudden cardiac death in hypertrophic cardiomyopathy.Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.Regulatory proteins alter nucleotide binding to acto-myosin of sliding filaments in motility assays Enhanced active cross-bridges during diastole: molecular pathogenesis of tropomyosin's HCM mutations Modifier genes for hypertrophic cardiomyopathy Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations.Investigating the effects of resveratrol on chronically ischemic myocardium in a swine model of metabolic syndrome: a proteomics analysis.Molecular biology of heart disease.Facilitated cross-bridge interactions with thin filaments by familial hypertrophic cardiomyopathy mutations in α-tropomyosin.The pathology of hypertrophic cardiomyopathy.Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes.Novel proteins associated with human dilated cardiomyopathy: selective reduction in α(1A)-adrenergic receptors and increased desensitization proteins.Transmission of stability information through the N-domain of tropomyosin is interrupted by a stabilizing mutation (A109L) in the hydrophobic core of the stability control region (residues 97-118).A study of tropomyosin's role in cardiac function and disease using thin-filament reconstituted myocardium.Genetic testing for inherited cardiac disease.Nuclear tropomyosin and troponin in striated muscle: new roles in a new locale?Alpha-tropomyosin mutations in inherited cardiomyopathies.Challenging current paradigms related to cardiomyopathies. Are changes in the Ca2+ sensitivity of myofilaments containing cardiac troponin C mutations (G159D and L29Q) good predictors of the phenotypic outcomes?A One Health Approach to Hypertrophic Cardiomyopathy.Calcium-dependent interaction sites of tropomyosin on reconstituted muscle thin filaments with bound Myosin heads as studied by site-directed spin-labeling.Overexpression of miRNA-9 Generates Muscle Hypercontraction Through Translational Repression of Troponin-T in Drosophila melanogaster Indirect Flight Muscles Several cardiomyopathy causing mutations on tropomyosin either destabilize the active state of actomyosin or alter the binding properties of tropomyosin.Familial hypertrophic cardiomyopathy mutations in troponin I (K183D, G203S, K206Q) enhance filament sliding.Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts.alpha-Tropomyosin mutations Asp(175)Asn and Glu(180)Gly affect cardiac function in transgenic rats in different ways.Myofilament lattice structure in presence of a skeletal myopathy-related tropomyosin mutation.Noncanonical roles for Tropomyosin during myogenesis.Overexpression of PGC-1α in aging muscle enhances a subset of young-like molecular patterns.Investigating the effects of tropomyosin mutations on its flexibility and interactions with filamentous actin using molecular dynamics simulation.Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.Identification of a founder mutation in TPM3 in nemaline myopathy patients of Turkish origin

P2860

07531b69557cc5be00b082bbdc999fed8b2f8c43 1557ecbe4e22fb32277a758988e64034ea68f0c9 452addf49d667c84e09499a8d3db39c14860f11c 8c34de0ed87c9c5e85fc81e311b835adf2384724

P248

Q21284968-151E8564-E646-440E-9EF9-CBCE4E58D870 Q25256135-487C0758-CDA7-436B-8F37-033F81B5DC83 Q27632998-F7BA68E7-84BC-40D8-B0A4-91DAE94B00B1 Q28307606-13D44E17-BFE5-4F5B-9DE0-D241FAFB8CC8 Q33921311-DB011E68-D418-47E0-BB4F-9F8668B12D31 Q34021080-1EEEF01C-3B16-442A-B351-4615DE23DCD0 Q34182303-92CAB883-3EA0-4A38-A5E5-BB53B256BCDB Q34568089-226F49DB-4F0F-46AE-B00C-5AF2069AD9EA Q34641881-9D8CB173-3EAE-4E71-A199-A90E7A8F23C7 Q34732430-D9EB3122-36AE-43AD-A88C-1D59A4621AD9 Q34802630-0A4B6057-2E19-4499-BF36-54DCD24B372D Q34863040-D481BF33-7719-4602-8472-0DC066501779 Q35610475-09C06820-0BB8-4D90-BD6A-9ABBF3BB3CC5 Q35771667-79E11688-830D-40B4-BEE2-0163AF9115C7 Q36369925-A9936FCF-8DA0-4C5C-8B97-259D9C492A46 Q36761037-759615A5-6924-44FA-9231-102BFD705A72 Q37583570-AFACFA87-E091-409D-A894-6EAA58050196 Q38108764-3B576BFA-F2DF-4108-81C7-1EC8E1759171 Q38125385-00DF44F6-5613-4326-9BA4-389A7060D183 Q38125907-D1F2DAB4-17DD-46E6-A01C-24261BF87B4E Q38134256-6D418F1F-D65E-4B98-A2CA-22F0D9B5F004 Q41679671-7F3C7298-C675-42B0-B52C-88C8E1CB6C54 Q41687674-C218728C-8882-426A-8BD5-12197377864B Q42183103-027C4E4E-932D-45EA-AA17-B29158C14B91 Q42373250-98A3BB94-578B-432B-A142-69B216C8E361 Q42689668-17B91915-5681-4971-9010-60019BB75771 Q44448940-C3219BE6-CDA4-4C0B-B05A-40A3A236E747 Q44758282-4BAEFC9C-6989-4CD7-A957-55EE444837B7 Q44805483-7140D5CB-5CDF-418C-9478-D2F4504B6EC7 Q46849807-9117286A-4040-4269-8593-BAB6654B1539 Q47070003-6030F277-EB41-4216-95FE-9216D09AB092 Q50088675-493E9852-15BA-4BF4-B7FE-C3ED8682A4A6 Q51664761-DCDC9C73-5136-47B2-A4B1-120B750425A3 Q51833897-03D8DE24-C8D6-49DF-964A-841B677A7C5E Q58185601-9116C8F3-8017-4A96-9858-72A8C54F042B

P2860

Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis

http://www.wikidata.org/entity/Q24290682

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@ast

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@en

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@en-gb

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@nl

type

label

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@ast

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@en

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@en-gb

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@nl

prefLabel

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@ast

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@en

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@en-gb

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@nl

P1433

Q24290682-F1C66C03-7DA7-4458-927F-473938FFE236

P1476

Q24290682-6736775C-0301-49A8-B8EE-346B51DD5EFC

P2093

Q24290682-2F34F10D-7F2E-45CE-A647-E05E53C7E953

Q24290682-4ABCA320-AA5B-4BC9-936F-97F4E908DE24

Q24290682-585C116F-D31F-4317-BE40-E030B147715C

Q24290682-699E38EE-B74D-454C-8D26-DC93EF4CE548

Q24290682-7752DD01-1102-43A4-B63C-81A7AB261FAB

Q24290682-7AA3CC0F-5656-4278-B051-431D9B46C9AA

Q24290682-7AA484FC-2B6C-45D1-B09A-632736439C96

Q24290682-C8C755DA-0966-43DC-85CF-E7ABC6E2292B

Q24290682-D52BA73F-98EF-4288-AAF1-9E355B0D4477

Q24290682-DD4C0E07-940F-46B2-B72D-A83E9CF0B931

P304

Q24290682-A9FE2C2E-379A-400E-ABB3-43FF1E6B219D

P31

Q24290682-F73DB8E8-4A9A-4EB7-A408-547B4B328E29

P356

Q24290682-00671F49-1177-48A3-BC56-DA96A929F7A5

P407

Q24290682-F3DF7E2D-5FC5-4FE5-98E5-94A3228CDBD8

P433

Q24290682-8EFDF92B-5891-4C78-9828-30069250D187

P478

Q24290682-135E4431-3839-4D28-B363-961F1FA396F6

P577

Q24290682-89429699-B24E-455A-BE3E-0B1E59D8A4A7

P698

Q24290682-9A7CFF77-271C-4BF6-9766-911AA37503FB

P921

Q24290682-60D4B537-13EA-4BD5-A042-3222531BB1AA

Q24290682-81A47C34-53C2-40AF-A8BB-A44A27B44717

P356

01.CIR.103.1.65

P1433

P1476

Hypertrophic cardiomyopathy ca ...... in cycling, and poor prognosis

@en

P2093

A E Arai

http://www.w3.org/2001/XMLSchema#string

A Karibe

http://www.w3.org/2001/XMLSchema#string

A Ortiz

http://www.w3.org/2001/XMLSchema#string

C Butters

http://www.w3.org/2001/XMLSchema#string

E Homsher

http://www.w3.org/2001/XMLSchema#string

J Strand

http://www.w3.org/2001/XMLSchema#string

L Fananapazir

http://www.w3.org/2001/XMLSchema#string

L L Bachinski

http://www.w3.org/2001/XMLSchema#string

L S Tobacman

http://www.w3.org/2001/XMLSchema#string

N Back

http://www.w3.org/2001/XMLSchema#string

P304

65-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.103.1.65

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2001-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11136687

http://www.w3.org/2001/XMLSchema#string

P921

cardiac muscle contraction